Therapies targeting DNA damage response show promising antitumor activity
Can cancer blood tests live up to promise of saving lives?
11 April 2022Heart issues after COVID-19 uncommon in children and young adults, more research needed
11 April 2022Therapies targeting DNA damage response show promising antitumor activity
Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers—ATR inhibitor elimusertib and PARP inhibitor AZD5305—are safe and clinically beneficial in treating patients with advanced solid tumors. Principal investigator Timothy Yap, M.B.B.S., Ph.D., associate professor of Investigational Cancer Therapeutics, today presented new data from the trials at the American Association for Cancer Research (AACR) Annual Meeting 2022.
